FI870502A - Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja - Google Patents

Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja Download PDF

Info

Publication number
FI870502A
FI870502A FI870502A FI870502A FI870502A FI 870502 A FI870502 A FI 870502A FI 870502 A FI870502 A FI 870502A FI 870502 A FI870502 A FI 870502A FI 870502 A FI870502 A FI 870502A
Authority
FI
Finland
Prior art keywords
producing
antibody
cell line
monoclonal antibodies
human monoclonal
Prior art date
Application number
FI870502A
Other languages
English (en)
Swedish (sv)
Other versions
FI870502A0 (fi
FI94489B (fi
FI94489C (fi
Inventor
Howard V Raff
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of FI870502A0 publication Critical patent/FI870502A0/fi
Publication of FI870502A publication Critical patent/FI870502A/fi
Publication of FI94489B publication Critical patent/FI94489B/fi
Application granted granted Critical
Publication of FI94489C publication Critical patent/FI94489C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI870502A 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja FI94489C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US82800586 1986-02-07
US94449586A 1986-12-19 1986-12-19
US94449586 1986-12-19

Publications (4)

Publication Number Publication Date
FI870502A0 FI870502A0 (fi) 1987-02-06
FI870502A true FI870502A (fi) 1987-08-08
FI94489B FI94489B (fi) 1995-06-15
FI94489C FI94489C (fi) 1995-09-25

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870502A FI94489C (fi) 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja

Country Status (28)

Country Link
US (2) US5717071A (fi)
JP (1) JP2645343B2 (fi)
KR (1) KR870007697A (fi)
CN (1) CN87102167A (fi)
AT (1) AT398781B (fi)
BE (1) BE1000967A5 (fi)
CA (1) CA1339013C (fi)
CH (1) CH672072A5 (fi)
DE (1) DE3703711A1 (fi)
DK (1) DK63187A (fi)
ES (1) ES2009140A6 (fi)
FI (1) FI94489C (fi)
FR (1) FR2595946B1 (fi)
GB (1) GB2186592B (fi)
GR (1) GR870194B (fi)
HK (1) HK21795A (fi)
HU (1) HU203583B (fi)
IE (1) IE59627B1 (fi)
IL (1) IL81370A (fi)
IT (1) IT1207589B (fi)
LU (1) LU86761A1 (fi)
MX (1) MX9203629A (fi)
NL (1) NL8700286A (fi)
NO (1) NO176924C (fi)
NZ (2) NZ219187A (fi)
OA (1) OA08477A (fi)
PT (1) PT84258B (fi)
SE (1) SE468747B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
EP0635132B2 (en) * 1992-03-19 2008-05-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies that react with common staphylococcal antigens
EP0680337A4 (en) * 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
WO1999054357A1 (fr) * 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Nouvelle proteine du type cytokine
CN101802198B (zh) * 2007-07-23 2016-02-17 圣诺菲·帕斯图尔有限公司 免疫原性多肽和单克隆抗体
US8444983B2 (en) * 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
EP3374391B1 (en) * 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CA3178465A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
AU567693B2 (en) * 1982-09-30 1987-12-03 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
NZ219187A (en) 1990-12-21
JP2645343B2 (ja) 1997-08-25
SE8700467L (sv) 1987-08-08
US5717071A (en) 1998-02-10
IL81370A (en) 1991-06-30
DK63187D0 (da) 1987-02-06
ATA26287A (de) 1994-06-15
NO176924B (no) 1995-03-13
PT84258A (en) 1987-03-01
GB8702689D0 (en) 1987-03-11
IE59627B1 (en) 1994-03-09
FR2595946A1 (fr) 1987-09-25
DK63187A (da) 1987-08-08
CH672072A5 (fi) 1989-10-31
HK21795A (en) 1995-02-24
GB2186592B (en) 1990-08-01
SE8700467D0 (sv) 1987-02-06
NL8700286A (nl) 1987-09-01
FI870502A0 (fi) 1987-02-06
NO870476L (no) 1987-08-10
JPS62270535A (ja) 1987-11-24
GB2186592A (en) 1987-08-19
SE468747B (sv) 1993-03-15
NO870476D0 (no) 1987-02-06
US5837541A (en) 1998-11-17
IT1207589B (it) 1989-05-25
LU86761A1 (fr) 1987-09-15
HU203583B (en) 1991-08-28
FI94489B (fi) 1995-06-15
FR2595946B1 (fr) 1991-10-04
BE1000967A5 (fr) 1989-05-30
PT84258B (pt) 1989-09-14
NO176924C (no) 1995-06-21
KR870007697A (ko) 1987-09-21
GR870194B (en) 1987-06-10
IL81370A0 (en) 1987-08-31
NZ233920A (en) 1990-12-21
FI94489C (fi) 1995-09-25
IT8719292A0 (it) 1987-02-06
CN87102167A (zh) 1988-02-03
DE3703711A1 (de) 1987-09-24
ES2009140A6 (es) 1989-09-01
IE870320L (en) 1987-08-07
AT398781B (de) 1995-01-25
HUT46062A (en) 1988-09-28
MX9203629A (es) 1992-07-01
CA1339013C (en) 1997-03-25
OA08477A (fr) 1988-07-29
DE3703711C2 (fi) 1993-06-24

Similar Documents

Publication Publication Date Title
FI870502A (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
FI873948A (fi) Menetelmä ihmisen kasvainkuoliotekijän (TNF) kanssa reagoivan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridisolulinja
IL76142A0 (en) Monoclonal antibody specific to human carcinoma tumorassociated antigen,hybrid cell lines producing the same and methods for the use thereof
HU896763D0 (en) Process for the preparation of bispecific monoclonal antibody
RO89963A (ro) Procedeu pentru prepararea unor difluoronucleozide
KR890700172A (ko) 금속-제2상 복합체 생산방법 및 그 생산물
ZA887987B (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
NZ217339A (en) Immunoassay for progesterone using monoclonal antibodies
PT87688A (pt) Hybrid protein c and method for its preparation
NO302176B1 (no) Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen
HUT43104A (en) Process for producing human antibodies
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
BG60017B2 (en) Method for reducing the heterogeneity of monoclonal antibodies
DE3689868T2 (de) Monoklonale Antikörper gegen menschliches Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und Verwendung.
FR2606421B1 (fr) Anticorps monoclonaux antigram (-) procede de preparation et applications
EP0185391A3 (en) Method for the purification of the hbc antigen and method for the measurement of hbc antibodies by using said purified hbc antigen
EP0267601A3 (en) Anti-pci monoclonal antibody
DK717888D0 (da) Monoklonale antistoffer
EP0157574A3 (en) Antitetanic antibody producing human-human hybridoma and method of producing the same
DE69024871T2 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
DK144485D0 (da) Monoklonale antistoffer
ES546110A0 (es) Procedimiento de producir factor viii-r humano
EP0218587A4 (en) MONOCLONAL ANTIBODIES AND IMMUNIZATION METHOD USING THE SAME.
EP0307476A4 (en) Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
ES555741A0 (es) Un metodo para producir anticuerpos monoclonales humanos

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BRISTOL-MYERS SQUIBB COMPANY

BB Publication of examined application
GB Transfer or assigment of application

Owner name: BRISTOL-MYERS SQUIBB COMPANY

FD Application lapsed
MM Patent lapsed

Owner name: BRISTOL-MYERS SQUIBB COMPANY